Efficacy and Safety of Immediate Angioplasty Versus Ischemia-Guided Management After Thrombolysis in Acute Myocardial Infarction in Areas With Very Long Transfer Distances

Results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-Elevation Myocardial Infarction)

Ellen Bøhmer, MD,* Pavel Hoffmann, MD, PtD,† Michael Abdelnoor, PtD,‡ Harald Arnesen, MD, PtD,§ Sigrun Halvorsen, MD, PtD*
Oslo and Lillehammer, Norway

Objectives
The goal of this study was to compare a strategy of immediate transfer for percutaneous coronary intervention (PCI) with an ischemia-guided approach after thrombolysis in patients with very long transfer distances to PCI.

Background
Thrombolysis remains the treatment of choice in ST-segment elevation myocardial infarction (STEMI) when primary PCI cannot be performed within 90 to 120 min. The optimal treatment after thrombolysis is still unclear.

Methods
A total of 266 patients with acute STEMI living in rural areas with more than 90-min transfer delays to PCI were treated with tenecteplase, aspirin, enoxaparin, and clopidogrel and randomized to immediate transfer for PCI or to standard management in the local hospitals with early transfer, only if indicated for rescue or clinical deterioration. The primary outcome was a composite of death, reinfarction, stroke, or new ischemia at 12 months, and analysis was by intention to treat.

Results
The primary end point was reached in 28 patients (21%) in the early invasive group compared with 36 (27%) in the conservative group (hazard ratio: 0.72, 95% confidence interval: 0.44 to 1.18, \( p = 0.19 \)). The composite of death, reinfarction, or stroke at 12 months was significantly reduced in the early invasive compared with the conservative group (6% vs. 16%, hazard ratio: 0.36, 95% confidence interval: 0.16 to 0.81, \( p = 0.01 \)). No significant differences in bleeding or infarct size were observed.

Conclusions
Immediate transfer for PCI did not improve the primary outcome significantly, but reduced the rate of death, reinfarction, or stroke at 12 months in patients with STEMI, treated with thrombolysis and clopidogrel in areas with long transfer distances. (Norwegian Study on District Treatment of ST-Elevation Myocardial Infarction; NCT00161005).

(J Am Coll Cardiol 2010;55:102–10) © 2010 by the American College of Cardiology Foundation

Primary percutaneous coronary intervention (PCI) is the preferred treatment for patients with ST-segment elevation myocardial infarction (STEMI), if it can be delivered in a timely manner by an experienced team (1,2). However, in rural areas with long transfer distances to PCI centers, primary PCI cannot be performed within the recommended time limits and thrombolysis remains the treatment of choice (2). The optimal treatment after thrombolysis is still unclear. Several studies have shown a beneficial effect of early transfer for coronary angiography and PCI if indicated, but the exact timing of angiography, the adjunctive antithrombotic medication, and the strategy for the conservative group in these studies have differed (3–7). Furthermore, few
of the studies have included patients with very long transfer distances. Long transfer distances to PCI might increase the need for early transfer in case of rescue indication, but also might increase the risk of complications.

Because more data are needed on the effects of early PCI after thrombolytic treatment for STEMI, we designed NORDISTEMI (NORwegian study on DIstrict treatment of ST-Elevation Myocardial Infarction) (8). The goal of this trial was to compare the effects of 2 reperfusion strategies both applied after full-dose thrombolysis: to transfer all patients immediately for PCI or to manage the patients more conservatively with an ischemia-guided strategy. The study was performed in a rural area with long transfer distances to PCI and widespread use of pre-hospital thrombolysis.

Methods

The design features of NORDISTEMI have been published previously (8).

Patient selection. The study was conducted in 5 community hospitals in the southeastern part of Norway, with the interventional facility located at Oslo University Hospital, Ulleval. Enrollment was performed between February 2005 and April 2008 in a pre-defined area with 100- to 400-km transfer distances to PCI and a well-established system for pre-hospital thrombolysis. Table 1 shows the inclusion and exclusion criteria. The protocol was approved by the Regional Committee for Medical Research Ethics, and all patients provided written, informed consent in accordance with the revised Declaration of Helsinki.

Study design. All patients received standard weight-adjusted dose tenecteplase, aspirin 300 mg orally, and enoxaparin 30 mg intravenously followed by a subcutaneous dose of 1 mg/kg repeated every 12 h up to hospital discharge or revascularization for a maximum of 7 days. All patients also received clopidogrel 300 mg on the first day (9).

Eligible patients were asked for participation at the same time as thrombolysis was given, and randomized in a 1:1 way to an early invasive or a conservative strategy. Permutated block randomization stratified by site, and sealed envelopes containing treatment modality according to random numbers were used. The random allocation sequence was generated at the Center for Clinical Research, Oslo University Hospital, Ulleval.

Patients assigned to the early invasive strategy were transferred to the PCI center as soon as possible after thrombolysis, for immediate coronary angiography and angioplasty of the infarct-related artery if indicated (≥50% diameter stenosis). The choice of stent type and use of glycoprotein IIb/IIIa inhibitor were at the operator’s discretion. Likewise, referral for surgery in case of left main coronary artery disease or serious 3-vessel disease was left to the judgment of the operator.

Patients assigned to conservative treatment were admitted to (in case of pre-hospital thrombolysis) or kept in the community hospitals for continued care, with referral for urgent angiography if persistent chest pain and <50% reduction of ST-segment elevation 60 min after initiation of thrombolysis (rescue indication) or hemodynamic instability. Referral for early coronary angiography was recommended if the patient had spontaneous recurrent ischemia with or without electrocardiogram (ECG) changes, or if signs of ischemia (chest pain, significant ST-segment changes, hypotension, or ventricular tachycardia) occurred in the exercise ECG recommended before hospital discharge. In all other patients, coronary angiography as a routine assessment after successful thrombolysis was encouraged within 2 to 4 weeks after discharge.

Beta-blockers and statins were administered to all patients unless contraindicated, angiotensin-converting enzyme inhibitors when indicated. Patients receiving stents were recommended clopidogrel 75 mg daily for 9 months. The other patients were recommended clopidogrel until angiography was performed or for 9 months, at the discretion of the treating physician. Complete clinical follow-up was performed at 3 and 12 months, and telephone follow-up was performed at 1 and 7 months. Troponin-T levels were measured in all patients the third morning after onset of STEMI, and myocardial perfusion single-photon emission computed tomography (SPECT) was scheduled after 3 months.

Table 1. Study Inclusion and Exclusion Criteria

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Age 18-75 yrs</td>
<td>1. Standard exclusion criteria for tenecteplase</td>
</tr>
<tr>
<td>2. Symptoms of myocardial infarction present for &lt;6 h</td>
<td>2. Cardiogenic shock or serious arrhythmias at randomization</td>
</tr>
<tr>
<td>3. ECG indicative of an acute STEMI: ≥2 mm ST-segment elevation in 2 contiguous precordial leads or ≥1 mm ST-segment elevation in 2 contiguous extremity leads or new left bundle branch block</td>
<td>3. Pregnancy</td>
</tr>
<tr>
<td>4. Expected time delay from first medical contact to PCI &gt;90 min</td>
<td>4. Known serious renal failure (serum creatinine &gt;250 mmol/l)</td>
</tr>
<tr>
<td>5. Receiving thrombolytic treatment with tenecteplase</td>
<td>5. Other diseases with life expectancy &lt;12 months</td>
</tr>
<tr>
<td>6. Informed consent for participation</td>
<td>6. Psychiatric disease, mental retardation, dementia, drug abuse, alcoholism, or conditions that can severely reduce compliance</td>
</tr>
</tbody>
</table>

Abbreviations and Acronyms

CI = confidence interval
ECG = electrocardiogram
HR = hazard ratio
IQR = interquartile range
PCI = percutaneous coronary intervention
SPECT = single-photon emission computed tomography
STEMI = ST-segment elevation myocardial infarction
TIMI = Thrombolysis In Myocardial Infarction
End points and definitions. The primary end point was a composite of death, reinfarction, stroke, or new myocardial ischemia at 12 months. Reinfarction in the first 18 h was defined as recurrent symptoms of ischemia at rest accompanied by new ST-segment elevation of $\geq 0.1$ mV in at least 2 contiguous leads, lasting $\geq 30$ min. After 18 h, the definition was: new Q waves in 2 or more leads, or new increase in concentrations of creatine kinase-MB or troponins above the upper limit of normal ($> 3\times$ upper limit of normal after PCI and $> 5\times$ upper limit of normal after coronary artery bypass graft), and $> 50\%$ higher than the previous value. Stroke was defined as a new focal, neurological deficit of vascular origin lasting more than 24 h. New myocardial ischemia was defined as unstable angina (chest pain at rest suspicious for coronary disease with or without ECG changes), recurrent angina grade II to IV (Canadian Cardiovascular Society classification) or serious arrhythmias (ventricular tachycardia/ventricular fibrillation) that appeared more than 12 h after randomization.

The secondary end points included a composite of death, stroke, or reinfarction at 12 months, transport-related complications, bleeding at 30 days, and infarct size. Bleeding complications were classified according to the GUSTO (Global Use of Strategies To Open coronary arteries) severity scale (10). Infarct size was assessed by SPECT (11,12), and by troponin T levels (13,14).

A blinded, independent Clinical Event Committee adjudicated all possible events related to the primary outcome. The SPECT analysis and processing of recordings and the evaluation of all angiograms were performed by people unaware of the clinical data and treatment allocation. An independent monitor verified a random sample of 20% of the patient data entry into the case-report forms against the patient’s medical records.

Statistical analysis. On the basis of previous reports (3–5), we anticipated that the occurrence of the primary end point would be 30% in the conservative group and 15% in the early invasive group. With a 2-sided alpha of 5% and a power of 80%, a total of 266 patients were required. Statistical analyses were performed according to the intention-to-treat principle. Continuous variables were expressed as median with interquartile range (IQR) or mean $\pm$ SD, and compared between groups using the Mann-Whitney $U$ test or 2-sample $t$ tests, respectively. Categorical variables were expressed as frequency (percentage) and compared using the chi-square test with Yates correction or Fisher exact test, as appropriate. Estimation of the cumulative primary event rate was performed with the Kaplan-Meier method, and events over time were compared using the log rank test. The Cox proportional hazards model was used to estimate the treatment effect as unadjusted hazard ratio (HR) with 95% confidence intervals (CIs). A 2-sided value of $p < 0.05$ was considered significant. Patient data and analysis results were managed in a database/analysis program (Epi Data/Epi Info version 3.4.3, 2007, Centers for Disease Control and Prevention, Atlanta, Georgia).

Results

Baseline characteristics. During the enrollment period, 524 patients were treated with thrombolysis for STEMI and screened for participation in the study, and 276 patients (53%) were subsequently included (Fig. 1). Ten patients were secondarily excluded because of violation of inclusion or exclusion criteria. Thus, 134 patients were left to follow-up in the early invasive and 132 in the conservative group. With the exception of 2 patients with very short time to treatment, all included patients had their STEMI diagnosis supported by increase of troponin concentrations above the upper limit of normal. In the conservative group, there was a higher prevalence of hypertension and a higher heart rate at randomization. Otherwise, the baseline characteristics were well balanced between the groups (Table 2).

Treatment received. Among all, 57% received thrombolysis in the pre-hospital setting, and time delay from symptom onset to thrombolysis was 123 min (IQR 80 to 195 min). Invasive procedures performed in the 2 groups are described in Table 3. Most patients in both groups were referred to coronary angiography, but the procedure was delayed by a median time of 5.5 days in the conservative compared with the early invasive group. The total number of PCI procedures was significantly higher in the early invasive group. In contrast, the number of coronary bypass grafts was higher in the conservative group ($p = NS$).

In the conservative group, 36 patients (27%) were transferred for rescue coronary intervention, and 32 patients underwent rescue PCI. Distances, delays, and Thrombolysis In Myocardial Infarction (TIMI) flow grade in this rescue group, compared with the early invasive group, are presented in Table 4. The rescue group had their PCI performed significantly later than the early invasive group, but no differences in the rate of TIMI flow grade 3 were observed, neither before nor after PCI (Table 4). Of the remaining 96 patients, 89 underwent angiography at a median time of 11 days (IQR 3 to 23 days) after randomization, and PCI was performed in 62 patients (65%); TIMI flow grade 3 was found in 77 of these patients (87%) before intervention.

At discharge, 98% of patients were prescribed aspirin, 92% clopidogrel, 90% beta-blockers, and 99% statins, with no difference between groups. The use of agents acting on the renin-angiotensin system was higher in the conservative (60%) compared with the invasive (42%) group. At 1 year, medication was unchanged except for clopidogrel, which was used in only 21% of patients (no difference between groups). At 7 months, 83% of patients were still taking clopidogrel.

Clinical outcome. The clinical outcomes at 30 days and 12 months are listed in Table 5. The primary end point at 12
months occurred in 28 patients (21%) in the early invasive group and in 36 patients (27%) in the conservative group (HR: 0.72, 95% CI: 0.44 to 1.18, p = 0.19) (Fig. 2A). The secondary composite end point of death, stroke, or reinfarction at 12 months occurred in 8 patients (6%) in the early invasive group and in 21 patients (16%) in the conservative group (HR: 0.36, 95% CI: 0.16 to 0.81, p = 0.01) (Fig. 2B).

The overall mortality was 2.6%. The causes of death were cardiogenic shock (n = 3), intracranial hemorrhage (n = 2), cerebral infarction (n = 1), and cancer (n = 1).

At 30 days, the combined incidence of death, reinfarction, stroke, or new ischemia was significantly reduced in the early invasive compared with the conservative group (10% vs. 21%, relative risk: 0.49, 95% CI: 0.27 to 0.81, p = 0.01) (Fig. 2B). The overall mortality was 2.6%. The causes of death were cardiogenic shock (n = 3), intracranial hemorrhage (n = 2), cerebral infarction (n = 1), and cancer (n = 1).

No significant difference was observed in risk of bleeding between the 2 groups (Table 6). Only 2 patients (0.8%) received blood transfusion. All severe bleedings were caused by intracranial hemorrhages. In these 5 patients (1.9%), onset of symptoms was <12 h after thrombolysis.

The transfer distances from first medical contact to the PCI center were long, with a median distance of 158 km (IQR 129 to 200 km) in the early invasive group (Table 4). One patient (0.7%) died during transfer, and 4 (3%) were successfully defibrillated in the early invasive group. In the conservative group, 2 patients had ventricular tachycardia treated with intravenous drugs.

Infarct size. After 3 months, SPECT with determination of infarct size was performed in 125 (93%) patients in the early invasive and 120 patients (91%) in the conservative group. Eighty-two patients (34%) had no signs of infarction. Median infarct size, estimated as percent of the left ventricle, was 7% (IQR 0% to 24%) in the early invasive group compared with 6% (IQR 0% to 19%) in the conservative group (p = 0.29). Furthermore, no significant differ-
ence in third-day troponin-T concentration was found between the early invasive (n = 126) and the conservative group (n = 130) (1.75 μg/l [IQR 0.86 to 2.92 μg/l] vs. 2.08 μg/l [IQR 0.78 to 3.97 μg/l], p = 0.38).

**Table 2** Baseline Characteristics at Randomization

<table>
<thead>
<tr>
<th></th>
<th>Early Invasive Group (n = 134)</th>
<th>Conservative Group (n = 132)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>60 (55, 67)</td>
<td>61 (53, 68)</td>
<td>0.98</td>
</tr>
<tr>
<td>Men</td>
<td>107 (80%)</td>
<td>94 (71%)</td>
<td>0.13</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>26.5 (24.7, 30.0)</td>
<td>26.4 (24.1, 30.0)</td>
<td>0.21</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>5.2 (1.1)</td>
<td>5.4 (1.1)</td>
<td>0.11</td>
</tr>
<tr>
<td>Treated hypertension</td>
<td>33 (25%)</td>
<td>50 (38%)</td>
<td>0.03</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>8 (6%)</td>
<td>10 (8%)</td>
<td>0.78</td>
</tr>
<tr>
<td>Current or previous smoker</td>
<td>106 (79%)</td>
<td>104 (79%)</td>
<td>0.93</td>
</tr>
<tr>
<td>Family history of coronary heart disease</td>
<td>77 (58%)</td>
<td>78 (59%)</td>
<td>0.88</td>
</tr>
<tr>
<td>Previous angina</td>
<td>17 (13%)</td>
<td>17 (13%)</td>
<td>0.89</td>
</tr>
<tr>
<td>Previous myocardial infarction</td>
<td>15 (11%)</td>
<td>14 (11%)</td>
<td>0.97</td>
</tr>
<tr>
<td>Previous coronary bypass graft</td>
<td>4 (3%)</td>
<td>3 (2%)</td>
<td>1.0</td>
</tr>
<tr>
<td>Previous angioplasty</td>
<td>9 (7%)</td>
<td>12 (9%)</td>
<td>0.62</td>
</tr>
</tbody>
</table>

**Infarct location on ECG**

- Anterior: 59 (44%) vs. 51 (39%), p = 0.44
- New left bundle branch block: 4 (3%) vs. 0 (0%), p = 0.12
- Nonanterior: 71 (53%) vs. 81 (61%), p = 0.21

**Blood pressure before thrombolysis (mm Hg)**

- Systolic: 133.4 (22.9) vs. 134.2 (22.4), p = 0.74
- Diastolic: 80.7 (15.2) vs. 82.0 (15.9), p = 0.48

**Heart rate (beats/min)**

- 65.3 (14.6) vs. 70.7 (17.6), p = 0.02

**Time intervals (min)**

- Symptom onset to first medical contact: 67 (34, 122) vs. 65 (40, 135), p = 0.68
- Symptom onset to tenecteplase: 117 (80, 195) vs. 136 (80, 195), p = 0.72

**Pre-hospital tenecteplase**: 80 (60%) vs. 71 (54%), p = 0.40

Data are median (25th, 75th percentiles), mean (SD), or n (%). ECG = electrocardiogram; RAS = renin-angiotensin system.

**Discussion**

Even the best-organized networks between ambulance service, community hospitals, and PCI centers cannot make
primary PCI available in a timely manner to all patients with STEMI. The NORDISTEMI study was designed to assess the optimal treatment for patients with STEMI living in rural areas where thrombolysis is the primary revascularization therapy. The effect of early invasive treatment after thrombolysis in areas with very long transfer distances have not been evaluated previously.

In the NORDISTEMI study, the median transfer distance to PCI was 158 km, and the median transfer time was 130 min. The early invasive strategy was associated with a reduction in the primary end point at 12 months compared with a conservative strategy, but the reduction did not reach statistical significance. Recent trials evaluating the effect of early angioplasty after thrombolysis, including the recent TRANSFER-AMI (Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction) study (15), have reported a significantly improved outcome with an early invasive strategy (3–7,15,16). Timing of PCI after thrombolysis, control-group interventions, and definitions of end points have varied considerably among these trials and might contribute to this discrepancy. Furthermore, it should be noted that at 30 days, the composite of death, reinfarction, stroke, and new ischemia was significantly reduced in the invasive group, in accordance with previous trials (relative risk: 0.49, p = 0.03).

Both in our study and in the TRANSFER-AMI trial (15), an antithrombotic regimen including enoxaparin and clopidogrel was given in addition to full-dose tenecteplase. The early addition of clopidogrel to aspirin and fibrinolytic treatment has been shown to reduce the risk of cardiac events (9,17), but has not been used in previous trials investigating the effect of early PCI after thrombolysis. Compared with most previous studies (3,4,7), a more liberal referral for angiography in the conservative group was allowed, and 95% of patients underwent angiography at a medium time of 5.5 days after thrombolysis. This more aggressive treatment of the conservative group in our study, with liberal referral to coronary angiography

### Table 4

<table>
<thead>
<tr>
<th></th>
<th>Early Invasive Group (n = 134)</th>
<th>Conservative/Rescue Group (n = 36)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transport distance from first medical contact to PCI center (km)</td>
<td>158 (129, 200)</td>
<td>180 (132, 234)</td>
<td>0.39</td>
</tr>
<tr>
<td>Time from tenecteplase to arrival at catheterization laboratory (min)</td>
<td>130 (105, 155)</td>
<td>187 (149, 240)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Immediate/rescue PCI performed</td>
<td>118 (88%)</td>
<td>32 (89%)</td>
<td>1.0</td>
</tr>
<tr>
<td>Time from tenecteplase to first balloon (min)</td>
<td>162 (137, 189)</td>
<td>209 (193, 247)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Symptom onset to first balloon (min)</td>
<td>302 (236, 380)</td>
<td>340 (279, 400)</td>
<td>0.04</td>
</tr>
</tbody>
</table>

Data are median (25th, 75th percentiles) or n (%).

PCI = percutaneous coronary intervention; TIMI = Thrombolysis In Myocardial Infarction.

<table>
<thead>
<tr>
<th></th>
<th>Early Invasive Group (n = 134)</th>
<th>Conservative Group (n = 132)</th>
</tr>
</thead>
<tbody>
<tr>
<td>At 30 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death, reinfarction, stroke, or new ischemia</td>
<td>14 (10.0%)</td>
<td>28 (21.2%)</td>
</tr>
<tr>
<td>Death, reinfarction, or stroke</td>
<td>6 (4.5%)</td>
<td>13 (9.8%)</td>
</tr>
<tr>
<td>Death</td>
<td>3 (2.2%)</td>
<td>3 (2.3%)</td>
</tr>
<tr>
<td>Reinfarction</td>
<td>2 (1.5%)</td>
<td>7 (5.3%)</td>
</tr>
<tr>
<td>Stroke</td>
<td>3 (2.2%)</td>
<td>5 (3.8%)</td>
</tr>
<tr>
<td>Recurrent ischemia</td>
<td>8 (6.0%)</td>
<td>16 (12.1%)</td>
</tr>
<tr>
<td>At 12 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death, reinfarction, stroke, or new ischemia</td>
<td>28 (20.9%)</td>
<td>36 (27.3%)</td>
</tr>
<tr>
<td>Death, reinfarction, or stroke</td>
<td>8 (6.0%)</td>
<td>21 (15.9%)</td>
</tr>
<tr>
<td>Death</td>
<td>3 (2.2%)</td>
<td>4 (3.0%)</td>
</tr>
<tr>
<td>Reinfarction</td>
<td>4 (3.0%)</td>
<td>12 (9.1%)</td>
</tr>
<tr>
<td>Stroke</td>
<td>3 (2.2%)</td>
<td>7 (5.3%)</td>
</tr>
<tr>
<td>Recurrent ischemia</td>
<td>20 (15.0%)</td>
<td>20 (15.2%)</td>
</tr>
</tbody>
</table>

Data are n (%).
and early addition of clopidogrel, has probably reduced the difference between groups at 12 months. Furthermore, no high-risk characteristics were demanded for inclusion in our study. This benign risk profile of the cohort may have prevented the demonstration of a more significant benefit.

The risk reduction associated with an early invasive strategy in previous studies has mainly been attributed to reductions in reinfarction or recurrent ischemia. Our study was not powered to look at individual end points. However, the rate of new ischemia was numerically similar in both groups. New ischemia was approved as an end point without ECG changes, and this soft definition might have resulted in misclassification of some events. Therefore, the secondary composite end point of death, reinfarction, and stroke at 12 months should be noted, being significantly reduced in the early invasive group compared with the conservative group (HR: 0.36, p = 0.01).
The rate of bleeding was low and did not differ between groups. Use of radial approach in 86% of patients together with limited use of glycoprotein IIb/IIIa inhibitors (9%) were probably the main reasons for the low number of GUSTO minor and moderate bleedings (18). The rate of GUSTO severe bleeding was as reported in other trials (1.9%); however, the rate of intracranial hemorrhage was higher than expected (19). The heavy loading of patients with antithrombotic drugs might be of concern, but recent analysis has not shown any increase in intracranial hemorrhages when adding enoxaparin and clopidogrel to fibrinolytic treatment (20).

Trials such as the NORDISTEMI study, in which PCI is performed a few hours after fibrinolysis, are different from the approach of performing PCI immediately after fibrinolysis (facilitated PCI), which has been associated with no clinical benefit compared with primary PCI (21,22). The time between fibrinolysis and PCI might have been too short in these studies (90 to 104 min).

The optimal time window for early PCI after fibrinolysis is unsettled. Five recent studies investigating the effect of early PCI after fibrinolysis had intervals from fibrinolysis to PCI ranging from 2 to 17 h (3–5,7,15). In our study, the median time from fibrinolysis to PCI was 163 min (2.7 h) in the early invasive group. Although short delays, the incidence of death, reinfarction, or stroke at 30 days was low (4.5%). We might speculate that the antithrombotic cotherapy used in our study has mitigated the early thrombotic complications observed in the ASSENT-4 (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial (21), and that this antithrombotic regimen together with use of a radial approach, might allow a shorter time between fibrinolysis and PCI.

Information about the risk of adverse events during transfer of STEMI patients has mostly come from studies comparing transfer for primary PCI to local thrombolysis (1). Although considerably longer transfer distances in the NORDISTEMI study, the occurrence of transfer complications in the early invasive group was consistent with previous results.

The median infarct sizes determined by SPECT at 3 months were small and did not differ significantly between groups. One-third of patients had no visible infarctions at SPECT. The very short median time of 123 min from symptom onset to fibrinolysis, with 25% of patients treated within 80 min, might contribute to this high percentage of invisible infarctions (23). A previous trial has reported smaller infarct sizes with early angioplasty compared with conventional care after thrombolysis (24). Because of the long transfer distances in the NORDISTEMI study, median time from symptom onset to first balloon was 5 h in the early invasive group, being beyond the time limit for major myocardial salvage (25).

Both the small infarct sizes and the low 1-year mortality (2.6%) might reflect the short time to treatment obtained by means of a well-organized system for pre-hospital thrombolysis (26,27). Our study indicates a potential for improving reperfusion strategies for patients living in rural areas with long transfer distances to PCI. This may be achieved by applying a well-organized pharmacoinvasive approach including pre-hospital thrombolysis and rapid transfer to an invasive center.

Study limitations. This study was powered only to detect differences in the primary composite end point, but not for the individual components of the end point or for safety. Because of the design of the trial, infarct size was not assessed in the acute phase. The open-label design might have introduced some bias. However, the clinical end points were adjudicated by an event committee blinded to the allocated treatment, and infarct size was assessed without knowledge of treatment assignment.

Unfortunately, randomization was not entirely successful in producing balanced groups. It cannot be ruled out that the small imbalance might have had some confounding effect on the outcome.

The study did not question the superiority of timely primary PCI over thrombolysis. At the time when the NORDISTEMI study was initiated, transfer for primary PCI in areas with more than 2-h delays was not an option because of ethical reasons.

According to the inclusion and exclusion criteria, the conclusions of the study are applicable only to STEMI patients age <76 years with symptom onset <6 h, without cardiogenic shock at randomization and with long transfer delays to primary PCI.

Conclusions

Although the study did not show any significant reduction in the primary outcome at 12 months, the significant reduction in the composite of death, reinfarction, or stroke suggests that an early invasive strategy may be the preferred option in patients receiving thrombolytic therapy, also in areas with long transfer distances. These findings might be taken into consideration when making algorithms for treatment of STEMI in rural areas.

Acknowledgments

The authors thank the physician investigators and the ambulance personnel who contributed to patient enroll-
ment, the nursing staff at each participating center for assistance with follow-up, and the patients for their volunteer spirit. The authors also thank Arild Mangschau and Ivar Sønå Kristensen for support in study design, Tor Ole Klemtdal and Kolbjørn Forfang for serving as the Clinical Events Committee, Carin Müller for SPECT analysis, and Ingebjorg Seljeflot for study logistics, including blood sample handling.

Reprint requests and correspondence: Dr. Sigrun Halvorsen, Department of Cardiology, Oslo University Hospital, Ulleval, Kirkeveien 166, N-0407 Oslo, Norway. E-mail: sigrun.h@online.no.

REFERENCES


Key Words: acute myocardial infarction ■ ST-segment elevation ■ pre-hospital thrombolysis ■ percutaneous coronary intervention.

APPENDIX

For SPECT details and a complete list of contributors, committees, and sites, please see the online version of this article.